[go: up one dir, main page]

AR057772A1 - Derivados de imidazol como inhibidores de sintasa de aldosterona y aromatasa. composiciones farmaceuticas - Google Patents

Derivados de imidazol como inhibidores de sintasa de aldosterona y aromatasa. composiciones farmaceuticas

Info

Publication number
AR057772A1
AR057772A1 ARP060103664A ARP060103664A AR057772A1 AR 057772 A1 AR057772 A1 AR 057772A1 AR P060103664 A ARP060103664 A AR P060103664A AR P060103664 A ARP060103664 A AR P060103664A AR 057772 A1 AR057772 A1 AR 057772A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
hydrogen
aryl
group
Prior art date
Application number
ARP060103664A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37610275&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057772(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR057772A1 publication Critical patent/AR057772A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Este compuesto es inhibidor de la sintasa de aldosterona y de la aromatasa, y por lo tanto, se puede emplear para el tratamiento de un trastorno y de una enfermedad mediada por la sintasa de aldosterona o por la aromatasa. De conformidad con lo anterior, se puede utilizar en el tratamiento de hipocalemia, hipertension, insuficiencia cardíaca congestiva, fibrilacion auricular, insuficiencia renal, en particular insuficiencia renal cronica, restenosis, ateroesclerosis, síndrome X, obesidad, nefropatía, infarto post-miocardial, enfermedades cardíacas coronarias, inflamacion, mayor formacion de colágeno, fibrosis, tales como fibrosis cardíaca o miocardíaca, y remodelacion en seguida de hipertension y disfuncion endotelial, ginecomastia, osteoporosis, cáncer de prostata, endometriosis, fibroides uterinos, hemorragia uterina disfuncional, hiperplasia endometrial, enfermedad de ovario poliquístico, infertilidad, enfermedad de mama fibroquística, cáncer de mama, y mastopatía fibroquística. Finalmente, la presente también proporciona una composicion farmacéutica. Reivindicacion 1: Un compuesto de formula (1), en donde: n es 1, o 2, o 3; R es hidrogeno, alquilo C1-7, o alquenilo C1-7, estando el alquilo C1-7 y el alquenilo C1-7 opcionalmente sustituidos por 1 a 5 sustituyentes independientemente seleccionados a partir del grupo que consiste en -O-R8 y -N(R8)(R9), en donde R8 y R9 se seleccionan independientemente a partir del grupo que consiste en hidrogeno, alquilo C1-7, acilo, arilo y heteroarilo, cada uno de los cuales está además opcionalmente sustituido por 1 a 4 sustituyentes independientemente seleccionados a partir del grupo que consiste en halogeno, alcoxilo C1-7 y alquilo C1-7; o R es -C(O)O- R10, o -C(O)N(R11)(R12), en donde R10, R11 y R12 se seleccionan independientemente a partir del grupo que consiste en hidrogeno, alquilo C1-7, cicloalquilo C3-8, arilo, aril-alquilo C1-7, haloalquilo C1-7 y heteroarilo, cada uno de los cuales está además opcionalmente sustituido por 1 a 4 sustituyentes independientemente seleccionados a partir del grupo que consiste en halogeno, hidroxilo, alcoxilo C1-7, alquilo C1-7, y arilo, en donde R11 y R12, tomados junto con el átomo de nitrogeno con el que están unidos, forman opcionalmente un anillo de 3 a 8 miembros; R1, R2, R3, R4, y R5 se seleccionan independientemente a partir del grupo que consiste en hidrogeno, alquenilo C1-7, alquilo C1-7, cicloalquilo C3-8, halogeno, ciano, nitro, H2N-, haloalquilo C1-7, alcoxilo C1-7, cicloalcoxilo C3-8, ariloxilo, arilo, heteroarilo, -C(O)OR10, y -N(R13)(R14), estando el alquilo C1-7, alquenilo C1-7, alcoxilo C1-7, arilo y heteroarilo además opcionalmente sustituidos por 1 a 3 sustituyentes seleccionados a partir de alquilo C1-7, hidroxilo, halogeno, alcoxilo C1-7, nitro, ciano, dialquilo C1-7-amino, alcoxilo C1-7-alquilo C1-7-, y haloalquilo C1-7, teniendo el R10 el mismo significado que se define anteriormente, y R13 y R14 se seleccionan independientemente a partir del grupo que consiste en hidrogeno, alquilo C1-7, cicloalquilo C3-8, haloalquilo C1-7, haloalcoxilo C1-7, arilo y ciano, con la condicion de que no más de tres de R1, R2, R3, R4, y R5 son simultáneamente hidrogeno; R13 y R14, tomados junto con el átomo de nitrogeno con el que están unidos, forman opcionalmente un anillo de 3-8 miembros; R y R1, tomados juntos, forman opcionalmente un anillo de 5 a 6 miembros que contiene 0 o 1 heteroátomo seleccionado a partir de O, N, o S; R6 y R7 son independientemente hidrogeno, hidroxilo, alquilo C1-7, alcoxilo C1-7, fenilo, o bencilo, en donde fenilo y bencilo están opcionalmente sustituidos por 1 a 4 sustituyentes independientemente seleccionados a partir del grupo que consiste en halogeno, alcoxilo C1-7 y alquilo C1-7; cuando R6 y R7 están unidos al mismo átomo de carbono, opcionalmente forman una fraccion formula (2), en donde Ra y Rb son independientemente hidrogeno, alquilo C1-7, alcoxilo C1-7, acilo, -COOR15 o -COR15, siendo el R15 hidrogeno, alquilo C1-7, haloalquilo C1-7, arilo, o -NH2; o cuando R6 y R7 están unidos al mismo átomo de carbono, tomados junto con ese átomo de carbono, forman opcionalmente un anillo de 3 a 8 miembros; o una sal farmacéuticamente aceptable del mismo; o un isomero optico del mismo, o una mezcla de isomeros opticos.
ARP060103664A 2005-08-25 2006-08-23 Derivados de imidazol como inhibidores de sintasa de aldosterona y aromatasa. composiciones farmaceuticas AR057772A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71144205P 2005-08-25 2005-08-25

Publications (1)

Publication Number Publication Date
AR057772A1 true AR057772A1 (es) 2007-12-19

Family

ID=37610275

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103664A AR057772A1 (es) 2005-08-25 2006-08-23 Derivados de imidazol como inhibidores de sintasa de aldosterona y aromatasa. composiciones farmaceuticas

Country Status (33)

Country Link
US (4) US8314097B2 (es)
EP (3) EP1919916B8 (es)
JP (2) JP5225086B2 (es)
KR (3) KR101324872B1 (es)
CN (2) CN102408429B (es)
AR (1) AR057772A1 (es)
AU (1) AU2006283105C1 (es)
BR (1) BRPI0615095B8 (es)
CA (1) CA2619660C (es)
DK (1) DK1919916T3 (es)
EA (1) EA014940B1 (es)
EC (1) ECSP088201A (es)
ES (2) ES2417498T3 (es)
GT (1) GT200600381A (es)
HR (1) HRP20130797T1 (es)
IL (2) IL189024A (es)
JO (1) JO2882B1 (es)
MA (1) MA29771B1 (es)
MX (1) MX2008002545A (es)
MY (1) MY151601A (es)
NO (1) NO340854B1 (es)
NZ (1) NZ565476A (es)
PE (2) PE20100263A1 (es)
PH (1) PH12013502342A1 (es)
PL (1) PL1919916T3 (es)
PT (1) PT1919916E (es)
SG (1) SG165319A1 (es)
SI (1) SI1919916T1 (es)
TN (1) TNSN08082A1 (es)
TW (2) TWI487708B (es)
UA (1) UA96737C2 (es)
WO (1) WO2007024945A1 (es)
ZA (1) ZA200800589B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200716105A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
WO2008140708A1 (en) * 2007-05-09 2008-11-20 The Trustees Of The University Of Pennsylvania Use of hdac inhibitors for treatment of cardiac rhythm disorders
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
EP2435402B1 (en) 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
WO2011019882A1 (en) * 2009-08-12 2011-02-17 William Marsh Rice University Nanostructure-beta-blocker conjugates
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2507234B1 (en) 2009-11-30 2014-03-12 Novartis AG Imidazole derivatives as aldosterone synthase inhibitors
PT2523731T (pt) * 2010-01-14 2019-01-21 Novartis Ag Uso de um agente modificador de hormona adrenal
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
AR086665A1 (es) * 2011-06-14 2014-01-15 Lilly Co Eli Inhibidor de aldosterona sintasa y composiciones farmaceuticas
CN103648495A (zh) 2011-07-08 2014-03-19 诺华股份有限公司 在高甘油三酯对象中治疗动脉粥样硬化的方法
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
JP5749410B2 (ja) * 2012-01-17 2015-07-15 ノバルティス アーゲー ジヒドロピロロ［１，２−ｃ］イミダゾリルアルドステロンシンターゼまたはアロマターゼ阻害薬の新たな形態および塩
EP3321262B1 (en) 2012-03-01 2021-01-13 Array Biopharma, Inc. Serine/threonine kinase inhibitors
WO2013131879A1 (en) 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide
EP2836228B1 (en) * 2012-04-12 2024-03-20 Novartis AG Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
EA028583B1 (ru) 2013-02-14 2017-12-29 Новартис Аг Замещенные бис-фенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза)
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
HK1218252A1 (zh) 2013-07-25 2017-02-10 Novartis Ag 合成apelin多肽之生物结合物
JP2015093831A (ja) * 2013-11-08 2015-05-18 日本メジフィジックス株式会社 アルドステロン合成酵素阻害剤
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
BR112016030243B1 (pt) * 2014-07-07 2023-04-11 Recordati Ag Formas de dosagem farmacêuticas, seu processo de preparação, e usos de celulose microcristalina
US10020185B2 (en) 2014-10-07 2018-07-10 Samsung Sdi Co., Ltd. Composition for forming silica layer, silica layer, and electronic device
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
JP6877339B2 (ja) 2014-10-14 2021-05-26 ノバルティス アーゲー Ｐｄ−ｌ１に対する抗体分子およびその使用
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
US20160172188A1 (en) * 2014-12-16 2016-06-16 Samsung Sdi Co., Ltd. Rinse solution for silica thin film, method of producing silica thin film, and silica thin film
KR101833800B1 (ko) 2014-12-19 2018-03-02 삼성에스디아이 주식회사 실리카계 막 형성용 조성물, 실리카계 막의 제조방법 및 상기 실리카계 막을 포함하는 전자 소자
KR101837971B1 (ko) 2014-12-19 2018-03-13 삼성에스디아이 주식회사 실리카계 막 형성용　조성물, 실리카계 막, 및 전자 디바이스
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
WO2016109361A2 (en) * 2014-12-31 2016-07-07 Auspex Pharmaceuticals, Inc. 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase
CR20170338A (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
WO2016120821A1 (en) 2015-01-29 2016-08-04 Novartis Ag Process for the production of condensed imidazolo derivatives
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
KR20170014946A (ko) 2015-07-31 2017-02-08 삼성에스디아이 주식회사 실리카 막 형성용 조성물, 실리카 막의 제조방법 및 실리카 막
EP4424322A3 (en) 2015-12-17 2025-04-16 Novartis AG Antibody molecules to pd-1 and uses thereof
WO2017170765A1 (ja) * 2016-03-30 2017-10-05 田辺三菱製薬株式会社 新規含窒素複素環化合物
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
CA3040803A1 (en) 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor
CN107737125A (zh) * 2016-11-26 2018-02-27 王玉美 一种治疗药物流产后子宫出血的药物
WO2018165649A1 (en) 2017-03-10 2018-09-13 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
IL314302A (en) 2018-05-03 2024-09-01 Damian Pharma Ag R-Pedrazole for use in the treatment of aldosteronism
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
EP3887363A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
EP3887388A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
CN111592546B (zh) * 2020-05-26 2023-08-25 上海鲲博玖瑞医药科技发展有限公司 奥德司他的制备方法
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
JP2021195367A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
CN117580962A (zh) * 2021-05-19 2024-02-20 动量生物技术有限公司 通过基因表达分析检测肾脏疾病或受损的方法和系统
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
CN116262765B (zh) * 2021-12-14 2025-11-14 中国科学院大连化学物理研究所 一种光活化试剂及其制备方法以及在线粒体蛋白质组标记与鉴定中的应用
CN115304591B (zh) * 2022-07-08 2024-10-01 广州中医药大学(广州中医药研究院) 一种桥环甾体合成酶抑制剂及其制备方法和应用
US20240391941A1 (en) 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2161938A (en) 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
NL291944A (es) 1960-05-04
DE1236523C2 (de) 1962-02-15 1975-06-12 Sanol-Arzneimittel Dr. Schwarz Gmbh, 4019 Monheim Verfahren zur herstellung von basischen phenylaethern und deren salzen
US3228943A (en) 1962-06-11 1966-01-11 Lumilysergol derivatives
NL300886A (es) 1962-11-23
NL301580A (es) 1962-12-11
GB1069343A (en) 1963-09-10 1967-05-17 Ici Ltd Propanolamine derivatives
US3238215A (en) 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
FR1390056A (fr) 1964-04-21 1965-02-19 Holding Ceresia S A Procédé de préparation de nouveaux dérivés du tétrahydronaphtalène et produits conformes à ceux obtenus par le présent procédé ou procédé similaire
NL127065C (es) 1964-04-22
NL130749C (es) 1964-09-10
GB1078852A (en) 1964-09-30 1967-08-09 Ici Ltd Alkanolamine derivatives
US3466325A (en) 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
US3929836A (en) 1965-05-11 1975-12-30 Hoffmann La Roche 2-(2-Lower alkylamino-1-hydroxy-ethyl)-substituted benzofurans
CH472404A (de) 1966-03-04 1969-05-15 Sandoz Ag Verfahren zur Herstellung neuer Indolderivate
CH469002A (de) 1966-06-21 1969-02-28 Sandoz Ag Verfahren zur Herstellung neuer Indolderivate
US3961071A (en) 1967-02-06 1976-06-01 Boehringer Ingelheim Gmbh Therapeutic compositions and method
US3940489A (en) 1967-02-06 1976-02-24 Boehringer Ingelheim Gmbh Therapeutic compositions and method
DE1668055B2 (de) 1967-03-10 1973-09-06 Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt Basisch substituierte cyclopentylphenolaether, deren salze mit physiologisch vertraeglichen saeuren und verfahren zu deren herstellung
US3511836A (en) 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3857952A (en) 1967-12-22 1974-12-31 May & Baker Ltd Certain benzene derivatives useful in treating cardiac disorders
US4045482A (en) 1968-11-12 1977-08-30 Yamanouchi Pharmaceutical Co. Ltd. 4-(3-Isopropylamino-2-hydroxypropoxy indene
US3836671A (en) 1969-02-21 1974-09-17 Ici Ltd Alkanolamine derivatives for producing beta-adrenergic blockade
GB1285038A (en) 1969-02-21 1972-08-09 Ici Ltd Alkanolamine derivatives
US3655663A (en) 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
US3663570A (en) 1969-04-28 1972-05-16 Sankyo Co Coumarin derivatives
CA956632A (en) 1969-05-16 1974-10-22 Yoshitomi Pharmaceutical Industries Phenoxy-aminopropanol derivatives
US4012444A (en) 1969-07-08 1977-03-15 Allen & Hanburys Limited 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
US4018824A (en) 1969-11-28 1977-04-19 Teikoku Hormone Mfg. Co., Ltd. 1-Aryloxy-3-aminopropane derivatives
US3935259A (en) 1970-01-08 1976-01-27 Ciba-Geigy Corporation New amines and processes for their manufacture
US4038313A (en) 1970-01-08 1977-07-26 Ciba-Geigy Corporation Cycloalkylureido phenoxy propanolamines
SE354851B (es) 1970-02-18 1973-03-26 Haessle Ab
GB1308191A (en) 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
US3669968A (en) 1970-05-21 1972-06-13 Pfizer Trialkoxy quinazolines
US4059622A (en) 1970-05-27 1977-11-22 Imperial Chemical Industries Limited Alkanolamine derivatives
DE2130393C3 (de) 1970-06-22 1981-02-26 E.R. Squibb & Sons Inc., New York, N.Y. (V.St.A.) 6,7-Dihydroxy -5,6,7,8-tetrahydronaphthyloxyaminopropanole und ihre Salze mit Säuren sowie ihre Verwendung bei der Bekämpfung von Herzerkrankungen
FR2092895B1 (es) 1970-06-29 1973-07-13 Lafon Victor
CA989411A (en) 1971-05-13 1976-05-18 Kakenyaku Kako Co. Benzofuran derivatives and preparation thereof
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US3910924A (en) 1972-04-13 1975-10-07 Otsuka Pharma Co Ltd 3,4-Dihydrocarbostyril derivatives and a process for preparing the same
GB1435139A (en) 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
US3857981A (en) 1973-06-20 1974-12-31 Armour & Co Preserving red color in red meats
AT334385B (de) 1973-12-20 1976-01-10 Chemie Linz Ag Verfahren zur herstellung von neuen phenoxypropylaminderivaten und deren salzen
NL175059C (nl) 1974-02-23 Boehringer Mannheim Gmbh Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
GB1501632A (en) 1974-06-28 1978-02-22 Cm Ind Aromatic ketones having cardiovascular activity
US4129565A (en) 1975-07-11 1978-12-12 Nisshin Flour Milling Co., Ltd. Isocarbostyril derivatives
US4340541A (en) 1975-08-15 1982-07-20 Sandoz Ltd. 4-(2-Benzoyloxy-3-tert.-butylaminopropoxy-2-methyl indole
FR2330383A1 (fr) 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
GB1544872A (en) 1976-06-25 1979-04-25 Sterling Drug Inc 4-hydroxyphenylalkanolamine derivatives and preparation thereof
DE2645710C2 (de) 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
DE2733747C2 (de) 1977-07-27 1979-09-27 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 2,2 Dichlorhydrazobenzol
CA1147342A (en) 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
US4188390A (en) 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
IT1094076B (it) 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
SE8004087L (sv) 1980-06-02 1981-12-03 Haessle Ab Nya parasubstituerade 3-fenoxi-1-alkylaminopropanol-2-er med betareceptorblockerande egenskaper, samt forfarande for deras framstellning, farmaceutiska beredningar innehallande desamma, och metod att behandla akut ...
US4394382A (en) 1980-06-17 1983-07-19 Kowa Company, Ltd. Dihydrobenzopyran compounds and pharmaceutical composition comprising said compounds
US4463176A (en) 1982-09-13 1984-07-31 Mead Johnson & Company Process for resolution of optical isomers
US5428160A (en) 1982-12-21 1995-06-27 Ciba-Geigy Corporation Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4728645A (en) 1982-12-21 1988-03-01 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
DE3347565A1 (de) 1983-12-30 1985-07-11 Thomae Gmbh Dr K Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPS6354321A (ja) 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
US4937250A (en) 1988-03-07 1990-06-26 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
JPS6469518A (en) 1987-09-09 1989-03-15 Sumitomo Spec Metals Grinding of calcined powder for superconducting ceramics
US5057521A (en) 1988-10-26 1991-10-15 Ciba-Geigy Corporation Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
US5140034A (en) 1989-03-14 1992-08-18 Merck Sharp & Dohme Ltd. Five-membered ring systems with bonded imidazolyl ring substituents
US5066656A (en) * 1989-11-01 1991-11-19 Janssen Pharmaceutica N.V. Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
CA2026792A1 (en) * 1989-11-01 1991-05-02 Michael N. Greco (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives
NZ236440A (en) 1989-12-15 1993-07-27 Merck & Co Inc Reversal of sexual phenotype in poultry using an inhibitor of steroid biotransformation and/or aromatase inhibitor, poultry produced by this process
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5162337A (en) 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
AU654331B2 (en) 1991-03-30 1994-11-03 Kissei Pharmaceutical Co. Ltd. Succinic acid compounds
WO1992018132A1 (en) 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
CA2066369A1 (en) 1991-04-19 1992-10-20 Alex Elbrecht Control of sex differentiation in fish
CH683151A5 (de) 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
JPH05176659A (ja) 1991-04-26 1993-07-20 Merck & Co Inc 家禽における雌性表現型を転換するために抗ミュラー管ホルモンを単独またはアロマターゼ阻害剤と組合せて使用する方法
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
AU660930B2 (en) 1991-06-21 1995-07-13 Novo Nordisk A/S (S)(+)-2-ethoxy-4-(N-(1-(2-piperidinophenyl)-3-methyl-1- butyl)aminocarbonylmethyl)benzoic acid
DE10199058I2 (de) 1991-07-30 2006-04-27 Alcm Co Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
EP0618803A4 (en) 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
US5457102A (en) * 1994-07-07 1995-10-10 Janssen Pharmaceutica, N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives
PT625155E (pt) 1992-01-27 2002-01-30 Janssen Pharmaceutica Nv Derivados de 1h-benzimidazol substituidos por pirrolo-imidazolilo e imidazopiridinilo utilizados como inibidores de aromatase
US5272260A (en) 1992-01-29 1993-12-21 Abbott Laboratories Reagents and methods for the determination of glycohydrolytic enzymes
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5488510A (en) 1994-07-26 1996-01-30 Lemay; Edward J. Enhanced depth perception viewing device for television
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
TW313568B (es) 1994-12-20 1997-08-21 Hoffmann La Roche
JPH0971586A (ja) 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
ES2237850T3 (es) 1997-10-14 2005-08-01 Mitsubishi Pharma Corporation Compuestos de piperazina y su uso medicinal.
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6333335B1 (en) * 1999-07-23 2001-12-25 Merck & Co., Inc. Phenyl-protein transferase inhibitors
US6677341B2 (en) 1999-09-23 2004-01-13 Pharmacia Corporation (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
GB0008921D0 (en) 2000-04-11 2000-05-31 Smithkline Beecham Plc Method of treatment
BR0110079A (pt) 2000-04-12 2002-12-31 Novartis Ag Combinação de compostos orgânicos
CA2429133C (en) * 2000-11-17 2009-08-18 Takeda Chemical Industries, Ltd. Novel imidazole derivatives, production method thereof and use thereof
WO2003013526A1 (en) 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
CN104383554B (zh) 2002-09-06 2018-06-08 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
HUP0203976A3 (en) 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
EP1565463B1 (en) * 2002-11-18 2008-06-11 Novartis AG Imidazo[1,5a] pyridine derivatives and methods for treating aldosterone mediated diseases
ATE402180T1 (de) 2004-03-26 2008-08-15 Lilly Co Eli Verbindungen zur behandlung von dyslipidemie
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
DE102004037475A1 (de) 2004-07-30 2006-03-23 Heinrich, Hans-Werner, Prof. Dr. Filtersystem zur membrangetrennten, adsorptiven Behandlung partikelhaltiger Flüssigkeiten
TW200716105A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
HRP20150892T1 (hr) 2008-03-03 2015-09-25 Novartis Ag Spojevi i sastavi kao modulatori tlr-aktivnosti
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
EP2507234B1 (en) * 2009-11-30 2014-03-12 Novartis AG Imidazole derivatives as aldosterone synthase inhibitors

Also Published As

Publication number Publication date
EP1919916B1 (en) 2013-04-03
KR20130018985A (ko) 2013-02-25
EP1919916B8 (en) 2014-04-30
CN102408429B (zh) 2014-07-30
BRPI0615095A2 (pt) 2011-05-03
JP5658719B2 (ja) 2015-01-28
ES2527209T3 (es) 2015-01-21
US20070049616A1 (en) 2007-03-01
PT1919916E (pt) 2013-07-10
EA200800488A1 (ru) 2008-08-29
PL1919916T3 (pl) 2013-08-30
US20140357621A1 (en) 2014-12-04
PE20100263A1 (es) 2010-04-06
KR101324872B1 (ko) 2013-11-01
NO20081466L (no) 2008-05-23
IL189024A (en) 2013-11-28
EP1919916A1 (en) 2008-05-14
WO2007024945A8 (en) 2013-09-12
GT200600381A (es) 2007-03-28
HRP20130797T1 (en) 2013-09-30
CA2619660A1 (en) 2007-03-01
JP2013006852A (ja) 2013-01-10
PH12013502342A1 (en) 2015-11-16
CN101248078B (zh) 2012-01-04
AU2006283105C1 (en) 2011-03-10
CN101248078A (zh) 2008-08-20
EP2256118A1 (en) 2010-12-01
US20120277215A1 (en) 2012-11-01
TWI487708B (zh) 2015-06-11
ECSP088201A (es) 2008-03-26
UA96737C2 (ru) 2011-12-12
MY151601A (en) 2014-06-13
WO2007024945A1 (en) 2007-03-01
KR20130083470A (ko) 2013-07-22
JP5225086B2 (ja) 2013-07-03
SI1919916T1 (sl) 2013-09-30
EP2256118B1 (en) 2014-10-29
AU2006283105B2 (en) 2010-08-12
NZ565476A (en) 2011-06-30
IL189024A0 (en) 2008-08-07
JO2882B1 (en) 2015-03-15
AU2006283105A1 (en) 2007-03-01
SG165319A1 (en) 2010-10-28
DK1919916T3 (da) 2013-07-01
TWI382986B (zh) 2013-01-21
ES2417498T3 (es) 2013-08-08
US20130287789A1 (en) 2013-10-31
IL221869A (en) 2016-06-30
BRPI0615095B8 (pt) 2021-05-25
BRPI0615095B1 (pt) 2020-10-20
US9278969B2 (en) 2016-03-08
US8314097B2 (en) 2012-11-20
TNSN08082A1 (en) 2009-07-14
MA29771B1 (fr) 2008-09-01
NO340854B1 (no) 2017-07-03
TW200740822A (en) 2007-11-01
KR20080046637A (ko) 2008-05-27
CA2619660C (en) 2015-01-06
CN102408429A (zh) 2012-04-11
KR101549762B1 (ko) 2015-09-04
EP2270011A1 (en) 2011-01-05
EA014940B1 (ru) 2011-04-29
HK1117518A1 (en) 2009-01-16
JP2009506048A (ja) 2009-02-12
US8835646B2 (en) 2014-09-16
KR101549759B1 (ko) 2015-09-04
PE20070517A1 (es) 2007-06-21
MX2008002545A (es) 2008-03-14
TW201305175A (zh) 2013-02-01
ZA200800589B (en) 2009-04-29

Similar Documents

Publication Publication Date Title
AR057772A1 (es) Derivados de imidazol como inhibidores de sintasa de aldosterona y aromatasa. composiciones farmaceuticas
AR118123A2 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos, composición farmacéutica y combinación
AR040595A1 (es) Derivados de amina sustituida y metodos de uso
CO2020002745A2 (es) Compuestos de bisamida que activan el sarcómero y sus usos
AR115993A2 (es) Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
PE20240879A1 (es) Inhibidor sos1 y uso del mismo
AR089568A1 (es) Compuestos heterociclicos y sus metodos de usos
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR085283A1 (es) Antagonistas de hepcidina a base de sulfonaminoquinolina
AR056317A1 (es) Compuestos de oxindol y composicion farmaceutica
AR047890A1 (es) Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3
AR090191A1 (es) Derivados del acido fenil alcanoico como agonistas gpr
AR051026A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR066154A1 (es) Derivados de piperidina / piperazina
AR068635A1 (es) Derivados de 1, 1, 1 - trifluor - 2 - hidroxi - 3 - fenilpropano, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion del receptor de glucocorticoides.
AR100714A1 (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor
AR075367A1 (es) Inhibidores de glucosilceramida sintasa
AR112907A1 (es) Pirazoles inhibidores de monoacilglicerol lipasa (magl)
AR090572A1 (es) Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
AR116022A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
PE20190980A1 (es) Compuestos terapeuticos y metodos para utilizarlos
AR040724A1 (es) Compuesto de imidazopiridina, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento
PE20211456A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado
AR103582A1 (es) Ciclopropabenzofuranil-piridopirazindionas
AR117576A1 (es) Derivados de sulfinilaminobenzamida y sulfonilaminobenzamida

Legal Events

Date Code Title Description
FG Grant, registration